Indications for: BERINERT
Treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients.
Limitations of Use:
Safety and efficacy for prophylactic therapy have not been established.
Adults and Children:
Give 20 IU/kg by slow IV inj at a rate of approx. 4mL/min. Do not administer doses <20 IU/kg.
Discontinue immediately if hypersensitivity reactions are suspected. Have epinephrine inj available. Monitor patients with known risk factors for thromboembolic events (eg, indwelling venous catheter/access device, history of thrombosis, atherosclerosis, morbid obesity, immobility). Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Pregnancy. Nursing mothers.
Risk of thrombotic events with concomitant oral contraceptives or certain androgens.
Dysgeusia, increased severity of pain; hypersensitivity reactions, thromboembolic events.
To report infections that may have been transmitted by Berinert, call the CSL Behring Pharmacovigilance Department at (866) 915-6958.
Generic Drug Availability:
Single-use vial—1 (w. supplies)